Detalhe da pesquisa
1.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Haematologica
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328852
2.
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Vaccines (Basel)
; 11(9)2023 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37766168
3.
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
Lancet Haematol
; 3(2): e87-98, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26853648